1. Home
  2. IMCC vs PPCB Comparison

IMCC vs PPCB Comparison

Compare IMCC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IM Cannabis Corp.

IMCC

IM Cannabis Corp.

HOLD

Current Price

$0.38

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$0.11

Market Cap

1.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCC
PPCB
Founded
1980
2007
Country
Israel
Australia
Employees
N/A
2
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
1.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IMCC
PPCB
Price
$0.38
$0.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
196.3K
5.8M
Earning Date
05-14-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$63.88
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.10
52 Week High
$7.12
$10.69

Technical Indicators

Market Signals
Indicator
IMCC
PPCB
Relative Strength Index (RSI) 33.03 37.20
Support Level $0.30 N/A
Resistance Level $1.55 $0.13
Average True Range (ATR) 0.06 0.02
MACD 0.02 0.00
Stochastic Oscillator 35.43 6.27

Price Performance

Historical Comparison
IMCC
PPCB

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: